SOHO

Gamida Cell Reports Third Quarter 2022 Financial Results and Provides Company Update

Retrieved on: 
Monday, November 14, 2022
Research, Other Health, General Health, Pharmaceutical, Oncology, Biometrics, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, FDA, Health, Investment, Overalls, Society for Immunotherapy of Cancer, CBC, CAR, Prescription Drug User Fee Act, Hematological Cancer Research Investment and Education Act, NK, Lymphatic system, Cell, ASH, Cancer, Highbridge Capital Management, Letter, CRISPR, Safety, Society, PDUFA, NAM, Center for International Blood and Marrow Transplant Research, The Year's Best Science Fiction: Tenth Annual Collection, Growth, Hematology-Oncology and Stem Cell Transplantation Research Center, Immunotherapy, SOHO, SITC, Database, Patient, Pharmaceutical industry

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter ended September 30, 2022.

Key Points: 
  • Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today provided a business update and reported financial results for the quarter ended September 30, 2022.
  • Net loss for the third quarter of 2022 was $17.8 million, compared to a net loss of $23.2 million in the third quarter of 2021.
  • As of September 30, 2022, Gamida Cell had total cash, cash equivalents and investments of $61.3 million.
  • Strengthened financial position: In September 2022, Gamida Cell executed an underwritten public offering raising approximately $20 million, before deducting underwriting discounts, commissions and offering expenses.

CTI BioPharma Reports Third Quarter 2022 Financial Results

Retrieved on: 
Monday, November 7, 2022
Janus, Society, Ruxolitinib, Nasdaq, Pacritinib, Thrombocytopenia, Platelet, Data analysis, Annual general meeting, Operating cost, Bleeding, ID, Investment, Myeloproliferative neoplasm, ASH, Hematology-Oncology and Stem Cell Transplantation Research Center, Primary myelofibrosis, Vera, CTI, Growth, Galena Biopharma, FLT3, ALK2, Webcast, JAK2, Anemia, CTIC, Patient, Mastocytosis, Telephone, JAK1, BID, Haematopoiesis, SOHO, Safety, Syndrome, Cytokine, FDA, Pharmaceutical industry, ACVR1

SEATTLE, Nov. 7, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the third quarter ended September 30, 2022.

Key Points: 
  • ET
    SEATTLE, Nov. 7, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the third quarter ended September 30, 2022.
  • "In the third quarter, CTI continued to make strong progress with the U.S. commercial launch of VONJO, delivering net revenue of $18.2 million, a 48% increase in sales compared to the second quarter.
  • CTI will host a conference call and webcast to review its third quarter 2022 financial results and provide an update on business activities today, November 7, 2022, at 4:30 p.m.
  • "CTI BioPharma" and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions.

ImmunoGen Reports Recent Progress and Third Quarter 2022 Financial Results

Retrieved on: 
Friday, November 4, 2022
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Society, Bevacizumab, Ovarian cancer, FDA, PIN, Zenith Contract Services, Research, ImmunoGen, U.S. Securities and Exchange Commission, Clinical trial, Lilly, Oncology, Capital expenditure, National Comprehensive Cancer Network, Society of Gynecologic Oncology, Program, ESGO, Venetoclax, Company, Congress, BLA, Carboplatin, ASH, Gynecologic Oncology (journal), BPDCN, Journal of the National Comprehensive Cancer Network, PDUFA, Hematology-Oncology and Stem Cell Transplantation Research Center, Security (finance), IMGN, Control, Patient, Cancer, ADC, Maintenance, Azacitidine, ESMO, European Society of Gynaecological Oncology, COVID-19, Annual general meeting, Novartis, SOHO, NCCN, SGO, Acute myeloid leukemia, Standard of care, Risk, AML, György Enyedi (geographer), Vaccine, Pharmaceutical industry, Medical imaging, Platinum, Cryptocurrency

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2022.

Key Points: 
  • ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2022.
  • With an intense focus on execution, we are well positioned to transform ImmunoGen into a fully-integrated oncology company this year.
  • Total revenues were $15.4 million for the quarter ended September 30, 2022 compared to $9.2 million for the quarter ended September 30, 2021.
  • Operating expenses for the quarter ended September 30, 2022 were $92.8 million, compared with $43.4 million for the same quarter in 2021.

Sotherly Hotels Inc. Schedules Third Quarter 2022 Earnings Release and Conference Call

Retrieved on: 
Wednesday, October 12, 2022
International, Time management, Hyatt, Telephone, Webcast, Investor, NASDAQ, SOHO, Investment, REIT, Company, Acquisition, Internet, Hilton Worldwide, GLOBE, SIX Financial Information, Hotel

WILLIAMSBURG, Va., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Sotherly Hotels Inc. (NASDAQ: SOHO) (the Company) announced that the Company will report financial results for the third quarter 2022 prior to the market opening on Thursday, November 10, 2022.

Key Points: 
  • WILLIAMSBURG, Va., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Sotherly Hotels Inc. (NASDAQ: SOHO) (the Company) announced that the Company will report financial results for the third quarter 2022 prior to the market opening on Thursday, November 10, 2022.
  • A conference call for investors and other interested parties is scheduled for 10:00 a.m. Eastern Time (ET) that same day, at which time management will discuss the Companys third quarter 2022 results.
  • Sotherly Hotels Inc. is a self-managed and self-administered lodging REIT focused on the acquisition, renovation, upbranding and repositioning of upscale to upper-upscale full-service hotels in the Southern United States.
  • The Company owns hotels that operate under the Hilton Worldwide and Hyatt Hotels Corporation brands, as well as independent hotels.

Eutelsat Communications: First Quarter 2022-23 Revenues

Retrieved on: 
Wednesday, October 12, 2022
Technology, Mobile, Wireless, 5G, Satellite, Telecommunications, Audio, Video, Networks, Internet, Data Management, Telenor, Customer satisfaction, Pressure, Vodafone Mobile Connect USB Modem, Thales Alenia Space, Hispasat, Two-phase electric power, Professional video over IP, USS Olympia (C-6), Efficiency, Nilesat, Growth, General manager, Democratic republic, Contract, Mobile, SOHO, Eutelsat, Data, Gruppo TIM, FY, History of Microsoft Office, Privacy and the US government, Fourth, Erich Berneker, Government, Connectivity, Federal government of the United States, Congo, Recollections of Full Years, SME, Small and medium-sized enterprises, Leadership, Communications satellite, Renewable energy, Video game

Eva Berneke, Chief Executive Officer of Eutelsat Communications, said: First Quarter Revenues are in line with our expectations, and we confirm our financial objectives for the current and subsequent years.

Key Points: 
  • Eva Berneke, Chief Executive Officer of Eutelsat Communications, said: First Quarter Revenues are in line with our expectations, and we confirm our financial objectives for the current and subsequent years.
  • Total revenues for the First Quarter stood at 287 million, stable on a reported basis, and down by 4.5% like-for-like.
  • Revenues of the five Operating Verticals (ie, excluding Other Revenues) stood at 291 million.
  • Other Revenues amounted to (3) million in the First Quarter versus 3 million a year earlier and (2) million in the Fourth Quarter of FY 2021-22.

SELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations

Retrieved on: 
Thursday, September 29, 2022
Bioequivalence, Therapy, PK, WT1, Sex, COVID-19, MD, SLS, Â, Society, NEW, Company, Senior, SOHO, PH, Patient, Memorial Sloan Kettering Cancer Center, Hematology-Oncology and Stem Cell Transplantation Research Center, Terminology, Annual report, Cyclin-dependent kinase 9, Drug development, NASDAQ, GLOBE, SEC, Lymphoma, Drug, Rat, GPS, CDK9, Human, Pharmaceutical industry, Greater China

The bioequivalence study was performed to evaluate the effect of different formulations on GFH009s preclinical pharmacokinetic (PK) profile.

Key Points: 
  • The bioequivalence study was performed to evaluate the effect of different formulations on GFH009s preclinical pharmacokinetic (PK) profile.
  • Dr. Dragan Cicic, MD, Senior Vice President, Clinical Development, of SELLAS, presented the findings at this years Meeting of the Society of Hematologic Oncology (SOHO) in a poster titled Pharmacokinetics and Bioequivalence of Two Formulations of GFH009 Maleate Injection in Sprague Dawley Rats.
  • About SELLAS Life Sciences Group, Inc.
    SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.
  • These statements include, without limitation, statements related to preclinical data for GFH009, plans for further development of GFH009, and the potential for GFH009 as a drug development candidate.

Long-Term Data from Omidubicel Phase 3 Trial Demonstrates Overall Survival and Sustainable Durable Outcomes for Patients with Blood Cancers at the Society of Hematologic Oncology Meeting

Retrieved on: 
Thursday, September 29, 2022
Science, Stem Cells, Biotechnology, Research, Oncology, Health, Infectious Diseases, Clinical Trials, Hospital, Risk, Therapy, Safety, Infection, The Year's Best Science Fiction: Tenth Annual Collection, COVID-19, Nominal interest rate, Transplant, Twitter, Lymphatic system, FDA, Hematology, Phenotype, LinkedIn, Population, SOHO, Quality of life, Breakthrough therapy, Private Securities Litigation Reform Act, PDUFA, Haematopoiesis, U.S. Securities and Exchange Commission, NK, Patient, Immunotherapy, Facebook, Technology, Instagram, Cell, Standard of care, Hematology-Oncology and Stem Cell Transplantation Research Center, Bone marrow, B cell, Life, Research, Security (finance), Graft-versus-host disease, BLA, SEC, Mortality, NAM, Society, Pharmaceutical industry, EU

These data reinforce our commitment to advance transformational cell therapy research and underscore the potential of our NAM technology platform.

Key Points: 
  • These data reinforce our commitment to advance transformational cell therapy research and underscore the potential of our NAM technology platform.
  • The long-term, durable clinical benefit of omidubicel was observed at three years across a patient population that typically has a poor prognosis.
  • Learn More
    Overall well-being health-related quality of life scores for patients treated with omidubicel demonstrated clinical benefit compared to standard of care.
  • These data suggest clinically meaningful and sustained improvements in physical, functional, and overall well-being compared to umbilical cord blood transplantation.

EQS-News: MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL

Retrieved on: 
Wednesday, September 28, 2022
Adult, Apoptosis, Rash, Headache, ASCT, Infection, The Year's Best Science Fiction: Tenth Annual Collection, Lenalidomide, Incidence, Twitter, Bleeding, Food, FSE, ADCC, Diarrhea, Chills, Flushing, LinkedIn, Joint Planning and Development Office, SOHO, MorphoSys, FC, Immunotherapy, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Cancer, Lymphoid leukemia, B-cell lymphoma, CD19, Hematology-Oncology and Stem Cell Transplantation Research Center, Tafasitamab, Incyte, Bruise, ADCP, NASDAQ, Polyclinic, Fever, Society, Death, DLBCL, Medical imaging, Pharmaceutical industry, Vaccine, Neutropenia

At data cutoff (February 15, 2022), 27 of 80 patients (34%) had undergone treatment for at least 2 years, with a median duration of treatment of 4.3 years.

Key Points: 
  • At data cutoff (February 15, 2022), 27 of 80 patients (34%) had undergone treatment for at least 2 years, with a median duration of treatment of 4.3 years.
  • Of those 27, 23 patients were alive at data cutoff, and 13 remained on treatment, including six who were on treatment for at least 5 years.
  • A complete response was observed in 23 of the 27 patients, including four who were refractory to their primary therapy.
  • A partial response was seen in four patients, two of whom were still on treatment at data cutoff.

MorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL

Retrieved on: 
Wednesday, September 28, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Adult, Apoptosis, Rash, Headache, ASCT, Infection, The Year's Best Science Fiction: Tenth Annual Collection, Lenalidomide, Incidence, Twitter, Bleeding, Food, ADCC, FSE, Diarrhea, Chills, Flushing, LinkedIn, Joint Planning and Development Office, SOHO, FC, Immunotherapy, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Cancer, Lymphoid leukemia, B-cell lymphoma, CD19, Hematology-Oncology and Stem Cell Transplantation Research Center, Tafasitamab, Incyte, Bruise, ADCP, NASDAQ, Polyclinic, Fever, Oncology, Society, Death, DLBCL, Pharmaceutical industry, Medical imaging, Vaccine, Neutropenia, MorphoSys

At data cutoff (February 15, 2022), 27 of 80 patients (34%) had undergone treatment for at least 2 years, with a median duration of treatment of 4.3 years.

Key Points: 
  • At data cutoff (February 15, 2022), 27 of 80 patients (34%) had undergone treatment for at least 2 years, with a median duration of treatment of 4.3 years.
  • Of those 27, 23 patients were alive at data cutoff, and 13 remained on treatment, including six who were on treatment for at least 5 years.
  • A complete response was observed in 23 of the 27 patients, including four who were refractory to their primary therapy.
  • A partial response was seen in four patients, two of whom were still on treatment at data cutoff.

SELLAS Life Sciences Announces Poster Presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting

Retrieved on: 
Thursday, September 22, 2022
Therapy, WT1, The Year's Best Science Fiction: Tenth Annual Collection, COVID-19, SLS, Company, SOHO, Memorial Sloan Kettering Cancer Center, Hematology-Oncology and Stem Cell Transplantation Research Center, Terminology, Annual report, Drug development, NASDAQ, GLOBE, SEC, CDK9, GPS, Society, Pharmaceutical industry, Greater China

The poster presentation characterizes the preclinical pharmacokinetic (PK) profiles of two different formulations of GFH009 maleate, pH 4.5 and pH 6.0.

Key Points: 
  • The poster presentation characterizes the preclinical pharmacokinetic (PK) profiles of two different formulations of GFH009 maleate, pH 4.5 and pH 6.0.
  • Additional presentation details can be found below:
    About SELLAS Life Sciences Group, Inc.
    SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.
  • SELLAS lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types.
  • GPS has potential as a monotherapy or in combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications.